• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

CPhI Webinar: Trends and Advances in Patient Centric Drug Development - Watch On Demand

cphi-onlineJune 24, 2021

Tag: CPhI , SPI , Drug development

There is an emerging need for patient centric drug development, and in this recent webinar, Donald Loveday, Global Business Development Manager, SPI Pharma and Doug Hovey, Technical Development Manager, North America, SPI Pharma define patient centricity and discuss its impact on the drug development cycle.

They also review the current standard practices in drug development, identify the unmet needs in patient populations that result, and discuss emerging regulatory requirements and the implications for scientists and executives involved in drug development.


Previous:COVID-19 Healthcare Startup Curative Achieves SOC 2 Security Control Compliance

Next:Honeywell Survey Reveals Healthier Buildings Top the List of Back-to-Work Priorities

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

CPhI Webinar: Trends and Advances in Patient Centric Drug Development - Watch On Demand | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Factory Supply Spiro[2H-isoindole-2, 1'-piperazinium], 4*-(1,2- benzisothiazol-3-yl)octahydro-, (3aR

Factory Supply Spiro[2H-isoindole-2, 1'-piperazinium], 4*-(1,2- benzisothiazol-3-yl)octahydro-, (3aR
2-([1,1'-biphenyl]-4-yl)-7-bromo-9,9'-spirobi[fluorene]

2-([1,1'-biphenyl]-4-yl)-7-bromo-9,9'-spirobi[fluorene]
Spiro(1-azabicyclo[2,2,2]octane-3,2-oxirane)

Spiro(1-azabicyclo[2,2,2]octane-3,2-oxirane)
Neurokinin A (swinespinal cord) (9CI)

Neurokinin A (swinespinal cord) (9CI)
Spiramycin

Spiramycin
Tandospirone-d8

Tandospirone-d8
Spiramycin EP8.0 with GMP supplier Pharmaceutical API Antibiotic made in china

Spiramycin EP8.0 with GMP supplier Pharmaceutical API Antibiotic made in china
7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[fluorene-9,9'-xanthene]-2-carbonitrile

7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)spiro[fluorene-9,9'-xanthene]-2-carbonitrile
5-Boc-5-aza-spiro(2.3)hexane-1-carboxylic acid

5-Boc-5-aza-spiro(2.3)hexane-1-carboxylic acid
SPIRAMYCIN

SPIRAMYCIN

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service